Skip to main content
Erschienen in: Endocrine 3/2014

01.12.2014 | Endocrine Genetics/Epigenetics

Polymorphisms in NR3C1 gene associated with risk of metabolic syndrome in a Chinese population

verfasst von: Yu-Xiang Yan, Jing Dong, Jie Zhang, Fen Liu, Wei Wang, Ling Zhang, Yan He

Erschienen in: Endocrine | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Polymorphisms of the NR3C1 (glucocorticoid receptor) gene have been reported to be associated with altered glucocorticoids sensitivity and changes in body composition and metabolic parameters. This study explored the relationship between single nucleotide polymorphisms (SNPs) of the NR3C1 gene and metabolic syndrome (MetS) in a Chinese population. Fourteen tag-SNPs and five functionally important SNPs in the NR3C1 gene were genotyped in MetS patients (n = 431) and normal controls (n = 461) using the high-throughput Sequenom genotyping platform. Genotype, allelic and haplotype associations were examined using logistic regression and Haploview. There are four SNPs significantly associated with MetS. The T allele of rs2963156 was associated with an increased risk effect for MetS (adjusted OR = 1.66, 95 % CI 1.25–2.22, P = 0.001). By contrast, rs10052957 A allele carriers were significantly associated with a decreased risk of MetS (adjusted OR = 0.58, 95 % CI 0.42–0.80, P = 0.001). Rs41423247 GG genotype (adjusted OR = 2.01, 95 % CI 1.25–3.22, P = 0.004), and rs7701443 AA genotype (adjusted OR = 1.88, 95 % CI 1.24–2.83, P = 0.003) were significantly associated with an increased risk of MetS. Haplotype CGGA is risk conferring (adjusted OR = 1.53, 95 % CI 1.06–2.20, P = 0.023), whereas haplotype CCAG was protective (adjusted OR = 0.30, 95 % CI 0.20–0.47, P < 0.001). Polymorphism of NR3C1 gene is associated with MetS and may contribute to the susceptibility of MetS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat D.E. Moller, K.D. Kaufman, Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56, 45–62 (2005)PubMedCrossRef D.E. Moller, K.D. Kaufman, Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56, 45–62 (2005)PubMedCrossRef
2.
Zurück zum Zitat K.L. Tamashiro, R.R. Sakai, C.A. Shively, I.N. Karatsoreos, L.P. Reagan, Chronic stress, metabolism, and metabolic syndrome. Stress 14(5), 468–474 (2011)PubMedCrossRef K.L. Tamashiro, R.R. Sakai, C.A. Shively, I.N. Karatsoreos, L.P. Reagan, Chronic stress, metabolism, and metabolic syndrome. Stress 14(5), 468–474 (2011)PubMedCrossRef
3.
Zurück zum Zitat G.P. Chrousos, T. Kino, Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10, 213–219 (2007)PubMedCrossRef G.P. Chrousos, T. Kino, Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10, 213–219 (2007)PubMedCrossRef
4.
Zurück zum Zitat J. Zhou, J.A. Cidlowski, The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70, 407–417 (2005)PubMedCrossRef J. Zhou, J.A. Cidlowski, The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70, 407–417 (2005)PubMedCrossRef
5.
Zurück zum Zitat D. Duma, C.M. Jewell, J.A. Cidlowski, Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 102, 11–21 (2006)PubMedCrossRef D. Duma, C.M. Jewell, J.A. Cidlowski, Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 102, 11–21 (2006)PubMedCrossRef
6.
Zurück zum Zitat N.C. Nicolaides, Z. Galata, T. Kino, G.P. Chrousos, E. Charmandari, The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75, 1–12 (2010)PubMedCentralPubMedCrossRef N.C. Nicolaides, Z. Galata, T. Kino, G.P. Chrousos, E. Charmandari, The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75, 1–12 (2010)PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat S.W. Lamberts, A.T. Huizenga, P. de Lange, F.H. de Jong, J.W. Koper, Clinical aspects of glucocorticoid sensitivity. Steroids 61, 157–160 (1996)PubMedCrossRef S.W. Lamberts, A.T. Huizenga, P. de Lange, F.H. de Jong, J.W. Koper, Clinical aspects of glucocorticoid sensitivity. Steroids 61, 157–160 (1996)PubMedCrossRef
8.
Zurück zum Zitat P. Smit, H. Russcher, F.H. de Jong, A.O. Brinkmann, S.W. Lamberts, J.W. Koper, Differential regulation of synthetic glucocorticoids on gene expression levels of glucocorticoid-induced leucine zipper and interleukin-2. J. Clin. Endocrinol. Metab. 90, 2994–3000 (2005)PubMedCrossRef P. Smit, H. Russcher, F.H. de Jong, A.O. Brinkmann, S.W. Lamberts, J.W. Koper, Differential regulation of synthetic glucocorticoids on gene expression levels of glucocorticoid-induced leucine zipper and interleukin-2. J. Clin. Endocrinol. Metab. 90, 2994–3000 (2005)PubMedCrossRef
9.
Zurück zum Zitat E.F. van Rossum, S.W. Lamberts, Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59, 333–357 (2004)PubMedCrossRef E.F. van Rossum, S.W. Lamberts, Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59, 333–357 (2004)PubMedCrossRef
10.
Zurück zum Zitat R.C. Lin, X.L. Wang, B. Dalziel, I.D. Caterson, B.J. Morris, Association of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant. Obes. Res. 11, 802–808 (2003)PubMedCrossRef R.C. Lin, X.L. Wang, B. Dalziel, I.D. Caterson, B.J. Morris, Association of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant. Obes. Res. 11, 802–808 (2003)PubMedCrossRef
11.
Zurück zum Zitat R. Rosmond, Y.C. Chagnon, G. Holm, M. Chagnon, L. Pérusse, K. Lindell et al., A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes. Res. 8, 211–218 (2000)PubMedCrossRef R. Rosmond, Y.C. Chagnon, G. Holm, M. Chagnon, L. Pérusse, K. Lindell et al., A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes. Res. 8, 211–218 (2000)PubMedCrossRef
12.
Zurück zum Zitat E.F. Van Rossum, J.W. Koper, N.A. Huizenga, A.G. Uitterlinden, J.A. Janssen, A.O. Brinkmann et al., A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 51, 3128–3134 (2002)PubMedCrossRef E.F. Van Rossum, J.W. Koper, N.A. Huizenga, A.G. Uitterlinden, J.A. Janssen, A.O. Brinkmann et al., A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 51, 3128–3134 (2002)PubMedCrossRef
13.
Zurück zum Zitat E.F. Van Rossum, P.H. Roks, F.H. De Jong, A.O. Brinkmann, H.A. Pols, J.W. Koper et al., Characterization of a promoter polymorphism in the glucocorticoid receptor gene and its relationship to three other polymorphisms. Clin. Endocrinol. (Oxf) 61, 573–581 (2004)CrossRef E.F. Van Rossum, P.H. Roks, F.H. De Jong, A.O. Brinkmann, H.A. Pols, J.W. Koper et al., Characterization of a promoter polymorphism in the glucocorticoid receptor gene and its relationship to three other polymorphisms. Clin. Endocrinol. (Oxf) 61, 573–581 (2004)CrossRef
14.
Zurück zum Zitat E. Charmandari, T. Ichijo, W. Jubiz, S. Baid, K. Zachman, G.P. Chrousos et al., A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression. J. Clin. Endocrinol. Metab. 93, 4963–4968 (2008)PubMedCentralPubMedCrossRef E. Charmandari, T. Ichijo, W. Jubiz, S. Baid, K. Zachman, G.P. Chrousos et al., A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression. J. Clin. Endocrinol. Metab. 93, 4963–4968 (2008)PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat A.A. Syed, J.A. Irving, C.P. Redfern, A.G. Hall, N.C. Unwin, M. White et al., Association of glucocorticoid receptor polymorphism A3669G in exon 9beta with reduced central adiposity in women. Obesity (Silver Spring) 14, 759–764 (2006)CrossRef A.A. Syed, J.A. Irving, C.P. Redfern, A.G. Hall, N.C. Unwin, M. White et al., Association of glucocorticoid receptor polymorphism A3669G in exon 9beta with reduced central adiposity in women. Obesity (Silver Spring) 14, 759–764 (2006)CrossRef
16.
Zurück zum Zitat Porzezińska-Furtak J, Krzyżanowska-Świniarska B, Miazgowski T, Safranow K, Kamiński R. Hypothalamic-pituitary-adrenal axis activity, personality traits, and BCL1 and N363S polymorphisms of the glucocorticoid receptor gene in metabolically obese normal-weight women. Endocrine. 45. doi:10.1007/s12020-014-0187-0 (2014) Porzezińska-Furtak J, Krzyżanowska-Świniarska B, Miazgowski T, Safranow K, Kamiński R. Hypothalamic-pituitary-adrenal axis activity, personality traits, and BCL1 and N363S polymorphisms of the glucocorticoid receptor gene in metabolically obese normal-weight women. Endocrine. 45. doi:10.​1007/​s12020-014-0187-0 (2014)
17.
Zurück zum Zitat Y.X. Yan, J. Dong, L.J. Wu, S. Shao, J. Zhang, L. Zhang et al., Associations between polymorphisms in the glucocorticoid-receptor gene and cardiovascular risk factors in a Chinese population. J. Epidemiol. 23, 389–395 (2013)PubMedCentralPubMedCrossRef Y.X. Yan, J. Dong, L.J. Wu, S. Shao, J. Zhang, L. Zhang et al., Associations between polymorphisms in the glucocorticoid-receptor gene and cardiovascular risk factors in a Chinese population. J. Epidemiol. 23, 389–395 (2013)PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)PubMedCrossRef K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)PubMedCrossRef
19.
Zurück zum Zitat J. Galon, D. Franchimont, N. Hiroi, G. Frey, A. Boettner, M. Ehrhart-Bornstein et al., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB. J. 16, 61–71 (2002)PubMedCrossRef J. Galon, D. Franchimont, N. Hiroi, G. Frey, A. Boettner, M. Ehrhart-Bornstein et al., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB. J. 16, 61–71 (2002)PubMedCrossRef
20.
Zurück zum Zitat G.P. Chrousos, T. Kino, Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci. STKE. 2005, pe48 (2005)PubMed G.P. Chrousos, T. Kino, Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci. STKE. 2005, pe48 (2005)PubMed
21.
Zurück zum Zitat P.J. Bray, R.G. Cotton, Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Hum. Mutat. 21, 557–568 (2003)PubMedCrossRef P.J. Bray, R.G. Cotton, Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Hum. Mutat. 21, 557–568 (2003)PubMedCrossRef
22.
Zurück zum Zitat M. Panarelli, C.D. Holloway, R. Fraser, J.M. Connell, M.C. Ingram, N.H. Anderson et al., Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J. Clin. Endocrinol. Metab. 83, 1846–1852 (1998)PubMed M. Panarelli, C.D. Holloway, R. Fraser, J.M. Connell, M.C. Ingram, N.H. Anderson et al., Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J. Clin. Endocrinol. Metab. 83, 1846–1852 (1998)PubMed
23.
Zurück zum Zitat M. Panek, T. Pietras, A. Fabijan, M. Milanowski, L. Wieteska, P. Górski, P. Kuna, J. Szemraj, Effect of glucocorticoid receptor gene polymorphisms on asthma phenotypes. Exp. Ther. Med. 5, 572–580 (2013)PubMedCentralPubMed M. Panek, T. Pietras, A. Fabijan, M. Milanowski, L. Wieteska, P. Górski, P. Kuna, J. Szemraj, Effect of glucocorticoid receptor gene polymorphisms on asthma phenotypes. Exp. Ther. Med. 5, 572–580 (2013)PubMedCentralPubMed
24.
Zurück zum Zitat S.D. Detera-Wadleigh, I.J. Encio, D.Y. Rollins, D. Coffman, D. Wiesch, A Tth111I polymorphism on the 5′ flanking region of the glucocorticoid receptor gene (GRL). Nucleic Acids Res. 19, 1960 (1991)PubMedCentralPubMedCrossRef S.D. Detera-Wadleigh, I.J. Encio, D.Y. Rollins, D. Coffman, D. Wiesch, A Tth111I polymorphism on the 5′ flanking region of the glucocorticoid receptor gene (GRL). Nucleic Acids Res. 19, 1960 (1991)PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat E.F. Van Rossum, P.G. Voorhoeve, S.J. Te Velde, J.W. Koper, H.A.D. van de Waal, H.C. Kemper et al., The ER22, 23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J. Clin. Endocrinol. Metab. 89, 4004–4009 (2004)PubMedCrossRef E.F. Van Rossum, P.G. Voorhoeve, S.J. Te Velde, J.W. Koper, H.A.D. van de Waal, H.C. Kemper et al., The ER22, 23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J. Clin. Endocrinol. Metab. 89, 4004–4009 (2004)PubMedCrossRef
26.
Zurück zum Zitat A. Krupoves, D. Mack, C. Deslandres, E. Seidman, D.K. Amre, Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn’s disease. Pharmacogenet. Genomics 21, 454–460 (2011)PubMedCrossRef A. Krupoves, D. Mack, C. Deslandres, E. Seidman, D.K. Amre, Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn’s disease. Pharmacogenet. Genomics 21, 454–460 (2011)PubMedCrossRef
Metadaten
Titel
Polymorphisms in NR3C1 gene associated with risk of metabolic syndrome in a Chinese population
verfasst von
Yu-Xiang Yan
Jing Dong
Jie Zhang
Fen Liu
Wei Wang
Ling Zhang
Yan He
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0324-9

Weitere Artikel der Ausgabe 3/2014

Endocrine 3/2014 Zur Ausgabe

Pros and Cons in Endocrine Practice

Surgical treatment of prolactinomas: cons

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.